Catalyst Pharmaceuticals (CPRX) Gains from Sales and Divestitures (2015 - 2025)
Catalyst Pharmaceuticals posted quarterly Gains from Sales and Divestitures of $333865.0 for Q4 2025, down 8.5% year-on-year from $364861.0 in Q4 2024, and down 8.5% on a QoQ basis from $364861.0 in Q4 2024.
Catalyst Pharmaceuticals (CPRX) has 5 years of Gains from Sales and Divestitures data on file, last reported at $333865.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 8.5% year-over-year to $333865.0; the trailing twelve-month figure through Dec 2025 stood at $333865.0 (down 8.5% YoY), and the FY2025 full-year result was $333865.0, down 8.5% from the prior year.
- Gains from Sales and Divestitures for Q4 2025 stood at $333865.0, down from $364861.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $364861.0 in Q4 2024 and bottomed at $333865.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 333,865.00 |
| Dec 31, 2025 | 333,865.00 |
| Dec 31, 2024 | 364,861.00 |
| Dec 31, 2024 | 364,861.00 |
| Dec 31, 2017 | 26,667.00 |
| Dec 31, 2017 | 26,667.00 |
| Dec 31, 2016 | 26,667.00 |
| Dec 31, 2016 | 26,667.00 |
| Dec 31, 2015 | 26,666.00 |
| Dec 31, 2015 | 26,666.00 |